Clinical Pharmacology Group

Responsible Ana María Peiró Peiró



In the Clinical Pharmacology Group we investigate interindividual variability in drug response, especially in the area of pain and cognitive diversity. Our work focuses on the monitoring of adverse events and the use of pharmacogenetic markers to improve the benefit/risk of drugs. To this end, we have specific lines of work on drugs abuse and dependence, as well as sleep disorders. The analysis of sex/gender interaction is included as a cross-cutting theme in all of them.


Line1: Pharmacogenetics

The group is made up of researchers and trainees with expertise in the field of Pharmacogenetics. As a multidisciplinary group, is composed by specialists in various disciplines such as doctors, pharmacists, biologists and biotechnologists.

The group offers the medical and scientific community all its experience and know-how in the determination of genetic polymorphisms associated with clinical pathologies and the response to pharmacological treatments, as an approach to precision medicine. Currently, panels of gene polymorphisms linked to pharmacokinetics (metabolism and transport) and pharmacodynamics linked to the area of analgesics and psychotropic drugs are available in a predefined form. However, advice is offered on the design of personalised polymorphism/gene panels for the development of research studies: prospective, retrospective; by pathology, by gene, by drug; or at translational research level.

Line 2: Prevention of problematic drug use

To identify individual risk factors in the non-medical use of analgesics and psychotropic drugs, applied to pain medicine and also in other areas of health, such as sports medicine. There is also a line of work on the analysis of motivation and expectations, which can lead to these behaviours. The group has experience in training and prevention of doping.

Line 3: Research into sex/gender interaction in pain medicine

The group’s link with clinical services of the Hospital General Dr. Balmis de Alicante, allows the inclusion of the gender perspective in clinical research lines. This qualitative analysis of the influence of gender in the clinical management of diseases allows us to glimpse areas for improvement in order to achieve greater equity in our health system.

P. Barrachina, C. Margarit, J. Muriel, S. López‑Gil, V. López‑Gil, A. Vara‑González, B. Planelles, MM. Inda, D. Morales, AM. Peiró.
Oxycodone/naloxone versus tapentadol in real‑world chronic non‑cancer pain management: an observational and pharmacogenetic study.
Scientific Reports (2022).

P. Ballester, J. Muriel, AM. Peiró
CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia.
Expert Opin Drug Metab Toxicol (2022).

P. Ballester, C. Espadas, AC. Londoño, S. Almenara, V. Aguilar, C. Belda, E. Pérez, J. Muriel, AM. Peiró.
The challenge of detecting adverse events in adults with autism spectrum disorder who have intellectual disability.
Autism Research (2021).

J. Barrachina , J. Muriel , C. Margarit, B. Planelles , P. Ballester, M. Richart-Martínez, E. Cutillas, T. Zandonai, D. Morales, AM. Peiró.
Global Pain State Questionnaire: Reliability, Validity, and Gender Gap.
Archives of Internal Medicine Research (2021).

P. Ballester, A.L. Richdale, E.K. Baker, A.M. Peiro
Sleep in autism: a biomolecular approach to aetiology and treatment.
Sleep Medicine Reviews (2020).

M.Á. Pena, J. Muriel, M. Saiz-Rodríguez, A.M. Borobia, F. Abad-Santos, J. Frías, A.M. Peiró.
Effect of cytochrome P450 and ABCB1 polymorphisms on Imatinib pharmacokinetics after single-dose administration to healthy subjects.
Clinical Drug Investigation (2020).

C. Margarit, R. Roca, MM. Inda, J. Muriel, P. Ballester, A. Flor, D. Morales, AM. Peiró.
Sex Bias and Genotype Influence on Opioid Safety Profile in Chronic Low Back Pain.
The Clinical Journal of Pain (2020).

P. Ballester P, MJ. Martínez, MM. Inda, A. Javaloyes, AL. Richdale, J. Muriel, C. Belda, N. Toral, D. Morales, E. Fernández, AM. Peiró.
Evaluation of agomelatine for the treatment of sleep problems in adults with Autism Spectrum Disorder.
Journal of Psychopharmacology (2019).

J. Muriel, C. Margarit, J. Barrachina, P. Ballester, A. Flor, D. Morales, JF. Horga, E. Fernández, AM. Peiró.
Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Basic & Clinic Pharmacology & Toxicology (2019).

J. Muriel, C. Margarit, B. Planelles, MM. Inda, C. Puga, E. Cutillas, MJ. Serralta, JF. Horga, D. Morales, AM. Peiró.
OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients.
Annals of the New York Academy of Sciences (2018).

Gender biases in pain medicine: pharmacogenetics, pharmacokinetics and metabolomics (SESGEN).
Funding agency: Proyectos de Investigación Clinica Independiente (ICI 2020). Instituto de Salud Carlos III, ISCIII.
Duration: 2020-2024.
PI: Ana María Peiró


Development and validation of a prescription opioid dependence prediction model (PreDESOPI).
Funding agency: Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) – Fundación FISABIO – Fundación Navarro Tripodi. Duration: 2020 – 2023.
PI: Javier Muriel


Omic sciences applied to pain medicine with analysis of sex/gender interaction (SESGEN-OMIC).
Funding agency: Ayudas para la realización de Acciones entre investigadores de la Universidad Miguel Hernández e investigadores/profesionales del Hospital Universitari i Politècnic/Instituto de Investigación Sanitaria La Fe (AP2021-06).
Duration: 2021 – 2022.
PI: Ana María Peiró y María José Herrero.


Deprescription in patients with opioid dependence.
Funding agency: Programa Difunde. Universidad Miguel Hernández. Duration: 2020-2021.
PI: Ana María Peiró


Pharmacogenetics applied to new opioid drugs for chronic pain.
Funding agency: Universidad Miguel Hernández. Duration: 2017-2018.
PI: Ana María Peiró